Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day

Gabi Shemesh*, Elad Moisseiev*, Moshe Lazar1, Shimon Kurtz Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel*The first two authors contributed equallyPurpose: To evaluate the safety an...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Moisseiev E, Lazar M, Shemesh G, Kurtz S
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://doaj.org/article/5ea2556c1e334f54ba7405a536fac57e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:5ea2556c1e334f54ba7405a536fac57e
record_format dspace
spelling oai:doaj.org-article:5ea2556c1e334f54ba7405a536fac57e2021-12-02T08:53:09ZIntraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day1177-54671177-5483https://doaj.org/article/5ea2556c1e334f54ba7405a536fac57e2012-02-01T00:00:00Zhttp://www.dovepress.com/intraocular-pressure-reduction-of-fixed-combination-timolol-maleate-05-a9347https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Gabi Shemesh*, Elad Moisseiev*, Moshe Lazar1, Shimon Kurtz Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel*The first two authors contributed equallyPurpose: To evaluate the safety and efficacy in intraocular pressure (IOP) reduction of increasing Cosopt dosage from twice to three times a day.Methods: The study included patients with primary open-angle glaucoma or ocular hypertension. After a washout period, IOP was measured at baseline, after 4 weeks of treatment with Cosopt twice a day, and after another 4 weeks of treatment with Cosopt three times a day. Blood pressure, heart rate, and oxygen saturation levels were also recorded.Results: Twenty-nine eyes of 29 patients were included. Increasing Cosopt dosage resulted in a statistically significant (P < 0.001) additional reduction in IOP of 2.2 ± 1.58 mmHg (10.69% ± 7.49% of the baseline IOP values). There were no local or systemic adverse effects.Conclusion: Treatment with Cosopt three times a day was more effective in reducing IOP than twice a day, with no effect on safety.Keywords: Cosopt, timolol, dorzolamide, glaucoma, intraocular pressure, dosageMoisseiev E, Lazar MShemesh GKurtz SDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 283-287 (2012)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Moisseiev E, Lazar M
Shemesh G
Kurtz S
Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day
description Gabi Shemesh*, Elad Moisseiev*, Moshe Lazar1, Shimon Kurtz Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel*The first two authors contributed equallyPurpose: To evaluate the safety and efficacy in intraocular pressure (IOP) reduction of increasing Cosopt dosage from twice to three times a day.Methods: The study included patients with primary open-angle glaucoma or ocular hypertension. After a washout period, IOP was measured at baseline, after 4 weeks of treatment with Cosopt twice a day, and after another 4 weeks of treatment with Cosopt three times a day. Blood pressure, heart rate, and oxygen saturation levels were also recorded.Results: Twenty-nine eyes of 29 patients were included. Increasing Cosopt dosage resulted in a statistically significant (P < 0.001) additional reduction in IOP of 2.2 ± 1.58 mmHg (10.69% ± 7.49% of the baseline IOP values). There were no local or systemic adverse effects.Conclusion: Treatment with Cosopt three times a day was more effective in reducing IOP than twice a day, with no effect on safety.Keywords: Cosopt, timolol, dorzolamide, glaucoma, intraocular pressure, dosage
format article
author Moisseiev E, Lazar M
Shemesh G
Kurtz S
author_facet Moisseiev E, Lazar M
Shemesh G
Kurtz S
author_sort Moisseiev E, Lazar M
title Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day
title_short Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day
title_full Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day
title_fullStr Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day
title_full_unstemmed Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day
title_sort intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (cosopt) administered three times a day
publisher Dove Medical Press
publishDate 2012
url https://doaj.org/article/5ea2556c1e334f54ba7405a536fac57e
work_keys_str_mv AT moisseieveampnbsplazarm intraocularpressurereductionoffixedcombinationtimololmaleate05anddorzolamide2cosoptadministeredthreetimesaday
AT shemeshg intraocularpressurereductionoffixedcombinationtimololmaleate05anddorzolamide2cosoptadministeredthreetimesaday
AT kurtzs intraocularpressurereductionoffixedcombinationtimololmaleate05anddorzolamide2cosoptadministeredthreetimesaday
_version_ 1718398305867661312